Eli Lilly reported a 56% year-over-year revenue increase in Q1 2026, fueled by strong sales of obesity drug MOUNJARO ($8.66B, +125%) and diabetes drug ZEPBOUND ($4.16B, +80%). The company’s pipeline shows promising progress with the launch of FOUNDAYO and advancements in Retatrutide and Eloralintide. Double-digit growth in EBGLYSS and JAYPIRCA, along with upcoming label expansions, support a $2 billion increase in full-year 2026 revenue guidance. Analyst Terry Chrisomalis maintains a 'strong buy' rating, citing robust growth and multiple near-term clinical and regulatory milestones.
The alcohol use disorder (AUD) market is projected to expand at a 12.1% compound annual growth rate (CAGR) from 2026 to 2036, driven by unmet clinical needs and the development of novel therapies targeting new mechanisms like the 5-HT3 pathway and NO...
Novo Nordisk and Eli Lilly are competing in the obesity drug market with their GLP-1 pills, Wegovy and Foundayo, respectively. Both companies are preparing for Medicare to cover these drugs for weight loss at $50 per month starting July 1, which coul...
Eli Lilly's stock surged in premarket trading following positive results from a Phase 3 trial of its next-generation weight-loss drug, retatrutide. Presented at the American Diabetes Association conference, the trial showed that patients lost an aver...
A curated list of 50 high-quality dividend growth stocks has been tracked since September 1, 2024, focusing on valuation and future return potential. Year-to-date, this group underperformed broad indexes but included standout performers like LRCX and...
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
